Skip to main content

Pazopanib halves risk of progression in RCC: Commentary

Publication ,  Journal Article
George, DJ
Published in: Oncology Report
September 1, 2009

Duke Scholars

Published In

Oncology Report

EISSN

1548-5323

ISSN

1548-5323

Publication Date

September 1, 2009

Issue

FALL

Start / End Page

27

Related Subject Headings

  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. J. (2009). Pazopanib halves risk of progression in RCC: Commentary. Oncology Report, (FALL), 27.
George, D. J. “Pazopanib halves risk of progression in RCC: Commentary.” Oncology Report, no. FALL (September 1, 2009): 27.
George DJ. Pazopanib halves risk of progression in RCC: Commentary. Oncology Report. 2009 Sep 1;(FALL):27.
George, D. J. “Pazopanib halves risk of progression in RCC: Commentary.” Oncology Report, no. FALL, Sept. 2009, p. 27.
George DJ. Pazopanib halves risk of progression in RCC: Commentary. Oncology Report. 2009 Sep 1;(FALL):27.

Published In

Oncology Report

EISSN

1548-5323

ISSN

1548-5323

Publication Date

September 1, 2009

Issue

FALL

Start / End Page

27

Related Subject Headings

  • Oncology & Carcinogenesis